ISAVUCONAZOLE - THE NEW TRIAZOLE ANTIFUNGAL Preparation
The rising incidences of invasive fungal infections caused by both yeast and filamentous micromycetes, making it necessary for the improvement of the applied therapy of antifungal drugs. Among them triazoles occupies a key position. Problems associated with secondary resistance, tolerability, drug-drug interactions, as well as availability of certain formulations of triazoles make it necessary to develop new antifungals in this group. Isavuconazole is a new member of the second generation triazoles class with high in vitro activity against a large number of clinically important fungal pathogens, good pharmacokinetic parameters and safety profile. Isavuconazole available in the intravenous as well as oral form, and now after a number of clinical trials approved for use in the US and Europe for the treatment of invasive aspergillosis, and mucormycosis. A brief description of an isavuconazole is presented in this article.